Indigo Carmine
Rectal Neoplasms
Walter BrunnerDormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 89/ 100
Competitive context
15 Active assets in the Rectal Neoplasms cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eloxatin Chongqing University Cancer Hospital | Phase 3 | BB |
Ertapenem University of Ulm | Phase 4 | BB |
PROPOFOL Uppsala University | Phase 4 | BB |
FLUOROURACILUM Pei-Rong Ding | Phase 3 | BB |
Sevoflurane Uppsala University | Phase 4 | BB |
View all 46 →
Same molecule, other indications
Indigo Carmine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →